Should I buy or sell Exelixis stock right now?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exelixis in the last twelve months. There are currently 6 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" EXEL shares. View EXEL analyst ratings or view top-rated stocks .

What is Exelixis' stock price target for 2024?

15 Wall Street analysts have issued 1 year target prices for Exelixis' shares. Their EXEL share price targets range from $18.00 to $32.00. On average, they expect the company's stock price to reach $26.29 in the next year. This suggests a possible upside of 15.2% from the stock's current price. View analysts price targets for EXEL or view top-rated stocks among Wall Street analysts .

How have EXEL shares performed in 2024?

Exelixis' stock was trading at $23.99 at the beginning of the year. Since then, EXEL shares have decreased by 4.9% and is now trading at $22.82. View the best growth stocks for 2024 here .

Are investors shorting Exelixis?

Exelixis saw a decline in short interest during the month of March. As of March 31st, there was short interest totaling 6,830,000 shares, a decline of 17.2% from the March 15th total of 8,250,000 shares. Based on an average daily trading volume, of 2,340,000 shares, the days-to-cover ratio is presently 2.9 days. Approximately 2.3% of the shares of the stock are sold short. View Exelixis' Short Interest .

When is Exelixis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our EXEL earnings forecast .

How were Exelixis' earnings last quarter?

Exelixis, Inc. (NASDAQ:EXEL) announced its quarterly earnings results on Tuesday, February, 6th. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.25 by $0.02. The biotechnology company earned $479.65 million during the quarter, compared to analyst estimates of $481.23 million. Exelixis had a net margin of 11.35% and a trailing twelve-month return on equity of 8.57%.

What ETFs hold Exelixis' stock?

ETFs with the largest weight of Exelixis (NASDAQ:EXEL) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA) , First Trust NYSE Arca Biotechnology Index Fund (FBT) , Invesco Biotechnology & Genome ETF (PBE) , Virtus LifeSci Biotech Products ETF (BBP) , Range Cancer Therapeutics ETF (CNCR) , IQ U.S. Mid Cap R&D Leaders ETF (MRND) , iShares MSCI USA Small-Cap Min Vol Factor ETF (SMMV) and SPDR S&P Biotech ETF (XBI) .

What guidance has Exelixis issued on next quarter's earnings?

Exelixis updated its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.8 billion-$1.9 billion, compared to the consensus revenue estimate of $1.9 billion.

What is Michael M. Morrissey's approval rating as Exelixis' CEO?

75 employees have rated Exelixis Chief Executive Officer Michael M. Morrissey on Glassdoor.com . Michael M. Morrissey has an approval rating of 79% among the company's employees. 38.0% of employees surveyed would recommend working at Exelixis to a friend.

What other stocks do shareholders of Exelixis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Exelixis investors own include Micron Technology (MU) , NVIDIA (NVDA) , Advanced Micro Devices (AMD) , Gilead Sciences (GILD) , Intel (INTC) , Alibaba Group (BABA) , Incyte (INCY) , BioMarin Pharmaceutical (BMRN) , Vertex Pharmaceuticals (VRTX) and AbbVie (ABBV) .

Who are Exelixis' major shareholders?

Exelixis' stock is owned by many different retail and institutional investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.81%), Meditor Group Ltd (0.73%), Tealwood Asset Management Inc. (0.02%), Alaska Permanent Fund Corp (0.02%), Clearview Wealth Advisors LLC (0.01%) and BTC Capital Management Inc. (0.00%). Insiders that own company stock include Alan M Garber , Carl B Feldbaum , Christopher J Senner, Dana Aftab , David Edward Johnson , George Poste , Gisela Schwab , Jack L Wyszomierski, Jeffrey Hessekiel , Lance Willsey , Patrick J Haley, Patrick J Haley , Peter Lamb , Stelios Papadopoulos and Vincent T Marchesi . View institutional ownership trends .

How do I buy shares of Exelixis?

Shares of EXEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:EXEL

Exelixis (EXEL) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free EXEL Stock Alerts

$22.82

+0.12 (+0.53%)

(As of 04/16/2024 ET)

Compare

Today's Range: $22.53
▼
$23.08
50-Day Range: $20.17
▼
$23.92
52-Week Range: $18.08
▼
$24.34

Volume: 1.69 million shs
Average Volume: 2.29 million shs
Market Capitalization: $6.92 billion

P/E Ratio: 35.66
Dividend Yield: N/A
Price Target: $26.29

Get Exelixis alerts:

Exelixis MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.60 Rating Score
Upside/Downside: 15.2% Upside
$26.29 Price Target
Short Interest: Healthy
2.32% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.63
Upright™ Environmental Score
News Sentiment: 0.42
Based on 24 Articles This Week
Insider Trading: Acquiring Shares
$3.93 M Bought Last Quarter
Proj. Earnings Growth: 25.62%
From $1.21 to $1.52 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.99 out of 5 stars

Medical Sector

7th out of 930 stocks

Biological Products, Except Diagnostic Industry

3rd out of 153 stocks

3.3

Analyst's Opinion

Consensus Rating
Exelixis has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 9 buy ratings, 6 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Exelixis has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

5.0

Short Interest

Percentage of Shares Shorted
2.32% of the float of Exelixis has been sold short.
Short Interest Ratio / Days to Cover
Exelixis has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Exelixis has recently decreased by 17.21%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Exelixis does not currently pay a dividend.
Dividend Growth
Exelixis does not have a long track record of dividend growth.

4.3

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Exelixis has received a 64.48% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "VEGFR tyrosine kinase inhibitors", "Mitogen-activated protein kinase (MEK) inhibitors", and "Clinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Exelixis is -1.63.

2.5

News and Social Media Coverage

News Sentiment
Exelixis has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 24 news articles for Exelixis this week, compared to 7 articles on an average week.
Search Interest
Only 13 people have searched for EXEL on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.
MarketBeat Follows
10 people have added Exelixis to their MarketBeat watchlist in the last 30 days. This is an increase of 11% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Exelixis insiders have bought 167.61% more of their company's stock than they have sold. Specifically, they have bought $3,933,000.00 in company stock and sold $1,469,691.00 in company stock.
Percentage Held by Insiders
Only 2.90% of the stock of Exelixis is held by insiders.
Percentage Held by Institutions
85.27% of the stock of Exelixis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

4.4

Earnings and Valuation

Earnings Growth
Earnings for Exelixis are expected to grow by 25.62% in the coming year, from $1.21 to $1.52 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Exelixis is 35.66, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 138.17.
Price to Earnings Ratio vs. Sector
The P/E ratio of Exelixis is 35.66, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 219.96.
Price to Earnings Growth Ratio
Exelixis has a PEG Ratio of 0.60. PEG Ratios below 1 indicate that a company could be undervalued.
Price to Book Value per Share Ratio
Exelixis has a P/B Ratio of 3.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Exelixis Stock (NASDAQ:EXEL)

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

EXEL Stock Price History

30 days | 90 days | 365 days | Advanced Chart

EXEL Stock News Headlines

March 26, 2024 | insidertrades.com

Alan M. Garber Sells 19,205 Shares of Exelixis, Inc. (NASDAQ:EXEL) Stock

April 16, 2024 | businesswire.com

Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024

April 16, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 13, 2024 | americanbankingnews.com

Exelixis (NASDAQ:EXEL) Stock Price Down 3.9%

April 13, 2024 | americanbankingnews.com

Barclays Downgrades Exelixis (NASDAQ:EXEL) to Equal Weight

April 11, 2024 | msn.com

Exelixis slips as Barclays downgrades on lack of catalysts

April 11, 2024 | americanbankingnews.com

Exelixis (NASDAQ:EXEL) Rating Reiterated by JMP Securities

April 11, 2024 | americanbankingnews.com

Q1 2024 Earnings Forecast for Exelixis, Inc. (NASDAQ:EXEL) Issued By Zacks Research

April 16, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 10, 2024 | finance.yahoo.com

Ryvu Therapeutics Presents Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting

April 10, 2024 | markets.businessinsider.com

What Analysts Are Saying About Exelixis Stock

April 10, 2024 | stocknews.com

3 Biotech Gems Poised for April Breakthroughs

April 10, 2024 | markets.businessinsider.com

Buy Rating for Exelixis Amidst Positive Litigation Outlook and Cabozantinib Sales Performance

April 10, 2024 | americanbankingnews.com

Q4 2024 Earnings Forecast for Exelixis, Inc. (NASDAQ:EXEL) Issued By Zacks Research

April 5, 2024 | finance.yahoo.com

Exelixis, Inc.: No-Moat Exelixis Faces Cabozantinib Patent Losses; Early-Stage Pipeline Makes Progress

March 28, 2024 | seekingalpha.com

Exelixis: Patent Woes And Challenging Market Dynamics Make For A Testy 2024

March 28, 2024 | theglobeandmail.com

BMO chief strategist sees buying opportunity for these U.S. stocks

March 28, 2024 | markets.businessinsider.com

Buy Rating Affirmed on Kyverna Therapeutics Amid Anticipated Clinical Updates and Strong Financial Position

March 21, 2024 | finance.yahoo.com

Exelixis, Inc.'s (NASDAQ:EXEL) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?

March 13, 2024 | finanznachrichten.de

Ryvu Therapeutics Summarizes 2023 Fiscal Year and Provides Corporate Update

March 8, 2024 | fool.com

2 Biotech Stocks to Buy Hand Over Fist in March

March 7, 2024 | finance.yahoo.com

10 Mid-Cap Stocks with Insider Purchases

March 6, 2024 | investorplace.com

3 Cutting-Edge Biotech Stocks Sitting on the Brink of Success

March 5, 2024 | finance.yahoo.com

Exelixis, Inc.: Exelixis Earnings: Cabometyx Posts Strong Sales; Early-Stage Pipeline Makes Progress

February 29, 2024 | finance.yahoo.com

Is Now The Time To Put Exelixis (NASDAQ:EXEL) On Your Watchlist?

February 27, 2024 | businesswire.com

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March

February 27, 2024 | 247wallst.com

Stock Offerings Prompt Big Insider Buying

See More Headlines

Receive EXEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exelixis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/06/2024
Today: 4/16/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: Biotechnology
Current Symbol: NASDAQ:EXEL
CUSIP: 30161Q10
CIK: 939767
Web: www.exelixis.com
Phone: (650) 837-7000
Fax: 650-837-8300
Employees: 1,310
Year Founded: 1994

Price Target and Rating

Average Stock Price Target: $26.29
High Stock Price Target: $32.00
Low Stock Price Target: $18.00
Potential Upside/Downside: +15.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.60
Research Coverage: 15 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.64
Trailing P/E Ratio: 35.67
Forward P/E Ratio: 18.87
P/E Growth: 0.6
Net Income: $207.76 million
Net Margins: 11.35%
Pretax Margin: 14.07%
Return on Equity: 8.57%
Return on Assets: 6.81%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.34
Quick Ratio: 3.30

Sales & Book Value

Annual Sales: $1.83 billion
Price / Sales: 3.78
Cash Flow: $0.77 per share
Price / Cash Flow: 29.62
Book Value: $7.47 per share
Price / Book: 3.06

Miscellaneous

Outstanding Shares: 303,190,000
Free Float: 294,401,000
Market Cap: $6.92 billion
Optionable: Optionable
Beta: 0.54

Social Links

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Dr. Stelios Papadopoulos Ph.D. (Age 76)
Co-Founder & Chair of the Board
Comp: $109k
Dr. Michael M. Morrissey Ph.D. (Age 63)
CEO, President & Director
Comp: $2.31M
Mr. Christopher J. Senner (Age 56)
Executive VP & CFO
Comp: $1.09M
Mr. Jeffrey J. Hessekiel J.D. (Age 55)
Executive VP, General Counsel & Secretary
Comp: $959.68k
Mr. Patrick J. Haley M.B.A. (Age 48)
Executive Vice President of Commercial
Comp: $844.64k
Dr. Dana T. Aftab Ph.D. (Age 61)
Executive VP of Discovery and Translational Research & Chief Scientific Officer
Ms. Susan T. Hubbard
Executive Vice President of Public Affairs & Investor Relations
Ms. Laura Dillard
Executive Vice President of Human Resources
Dr. Peter Lamb Ph.D. (Age 63)
Executive VP of Scientific Strategy
Comp: $909.46k
Dr. Anne Champsaur M.D.
Senior Vice President of Drug Safety

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

EXEL Stock Analysis - Frequently Asked Questions

Should I buy or sell Exelixis stock right now?: 15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exelixis in the last twelve months. There are currently 6 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" EXEL shares.
View EXEL analyst ratings or view top-rated stocks.
What is Exelixis' stock price target for 2024?: 15 Wall Street analysts have issued 1 year target prices for Exelixis' shares. Their EXEL share price targets range from $18.00 to $32.00. On average, they expect the company's stock price to reach $26.29 in the next year. This suggests a possible upside of 15.2% from the stock's current price.
View analysts price targets for EXEL or view top-rated stocks among Wall Street analysts.
How have EXEL shares performed in 2024?: Exelixis' stock was trading at $23.99 at the beginning of the year. Since then, EXEL shares have decreased by 4.9% and is now trading at $22.82.
View the best growth stocks for 2024 here.
Are investors shorting Exelixis?: Exelixis saw a decline in short interest during the month of March. As of March 31st, there was short interest totaling 6,830,000 shares, a decline of 17.2% from the March 15th total of 8,250,000 shares. Based on an average daily trading volume, of 2,340,000 shares, the days-to-cover ratio is presently 2.9 days. Approximately 2.3% of the shares of the stock are sold short.
View Exelixis' Short Interest.
When is Exelixis' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our EXEL earnings forecast.
How were Exelixis' earnings last quarter?: Exelixis, Inc. (NASDAQ:EXEL) announced its quarterly earnings results on Tuesday, February, 6th. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.25 by $0.02. The biotechnology company earned $479.65 million during the quarter, compared to analyst estimates of $481.23 million. Exelixis had a net margin of 11.35% and a trailing twelve-month return on equity of 8.57%.

What ETFs hold Exelixis' stock?: ETFs with the largest weight of Exelixis (NASDAQ:EXEL) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), First Trust NYSE Arca Biotechnology Index Fund (FBT), Invesco Biotechnology & Genome ETF (PBE), Virtus LifeSci Biotech Products ETF (BBP), Range Cancer Therapeutics ETF (CNCR), IQ U.S. Mid Cap R&D Leaders ETF (MRND), iShares MSCI USA Small-Cap Min Vol Factor ETF (SMMV) and SPDR S&P Biotech ETF (XBI).
What guidance has Exelixis issued on next quarter's earnings?: Exelixis updated its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.8 billion-$1.9 billion, compared to the consensus revenue estimate of $1.9 billion.
What is Michael M. Morrissey's approval rating as Exelixis' CEO?: 75 employees have rated Exelixis Chief Executive Officer Michael M. Morrissey on Glassdoor.com. Michael M. Morrissey has an approval rating of 79% among the company's employees. 38.0% of employees surveyed would recommend working at Exelixis to a friend.
What other stocks do shareholders of Exelixis own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Exelixis investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Intel (INTC), Alibaba Group (BABA), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Vertex Pharmaceuticals (VRTX) and AbbVie (ABBV).
Who are Exelixis' major shareholders?: Exelixis' stock is owned by many different retail and institutional investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.81%), Meditor Group Ltd (0.73%), Tealwood Asset Management Inc. (0.02%), Alaska Permanent Fund Corp (0.02%), Clearview Wealth Advisors LLC (0.01%) and BTC Capital Management Inc. (0.00%). Insiders that own company stock include Alan M Garber, Carl B Feldbaum, Christopher J Senner, Dana Aftab, David Edward Johnson, George Poste, Gisela Schwab, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Patrick J Haley, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi.
View institutional ownership trends.
How do I buy shares of Exelixis?: Shares of EXEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:EXEL) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Exelixis (EXEL) Stock Price, News & Analysis

Exelixis MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Exelixis Stock (NASDAQ:EXEL)

EXEL Stock Price History

EXEL Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

EXEL Stock Analysis - Frequently Asked Questions

Overall MarketRank^™